Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
EMD
vs
S
S&P/ASX 300
EMD
Over the past 12 months, EMD has underperformed S&P/ASX 300, delivering a return of -30% compared to S&P/ASX 300's 4% drop.
Stocks Performance
EMD vs S&P/ASX 300
Performance Gap
EMD vs S&P/ASX 300
Performance By Year
EMD vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Emyria Ltd
Glance View
Emyria is an Australian healthcare company focused on mental health treatment and drug development. It runs specialist clinics and treatment programs for patients with complex mental health conditions, and it also works on new therapies such as psychedelic-assisted psychotherapy through clinical research and regulated treatment pathways. The company makes money mainly by charging for clinical services and by building programs, data sets, and research work that support its treatment model. Its main customers are patients seeking specialist care, along with clinicians and research partners involved in testing and delivering these therapies. What sets Emyria apart is that it sits between care delivery and drug development. Instead of only selling a medicine or only running a clinic, it tries to use its own treatment experience and patient data to build evidence for new mental health therapies and to create a repeatable clinical pathway around them.
